secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002704
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01, 7.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024
--------------------------------------------------------------------------------

- Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.
- CAHmelia-203 (N=96) and CAHptain-205 (N=30) enrollment complete, surpassing targets.
- CAHmelia-204 enrollment to finish Jan 2024 (N~98); topline results from CAHmelia-203 and CAHptain-205 expected March 2024.
- Baseline characteristics: CAHmelia-203 mean A4 1,149 ng/dL on 27 mg/day GC; CAHmelia-204 mean A4 214 ng/dL on 35 mg/day GC.
- Cash runway into first half of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/0000950170-24-002704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017024002704/sprb-20240104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer